STIM2 abnormality was closely correlated with immune TME indicating of poor prognosis, and the dysregulation of STIM2 in the stroma region was associated with the more invasive clinical phenotype and poor outcome in prostate cancer [76, 77] (Fig. 3). The gene discussed is STIM2; the disease is prostate carcinoma.